Identification and functional characterization of a novel ryanodine receptor mutation causing malignant hyperthermia in North American and South American families
- PMID: 11525881
- DOI: 10.1016/s0960-8966(01)00202-4
Identification and functional characterization of a novel ryanodine receptor mutation causing malignant hyperthermia in North American and South American families
Abstract
Malignant hyperthermia is a pharmacogenetic disorder associated with mutations in Ca(2+) regulatory proteins. It manifests as a hypermetabolic crisis triggered by commonly used anesthetics. Malignant hyperthermia susceptibility is a dominantly inherited predisposition to malignant hyperthermia that can be diagnosed by using caffeine/halothane contracture tests. In a multigenerational North American family with a severe form of malignant hyperthermia that has caused four deaths, a novel RYR1 A2350T missense mutation was identified in all individuals testing positive for malignant hyperthermia susceptibility. The same A2350T mutation was identified in an Argentinean family with two known fatal MH reactions. Functional analysis in HEK-293 cells revealed an altered Ca(2+) dependence and increased caffeine sensitivity of the expressed mutant protein thus confirming the pathogenic potential of the RYR1 A2350T mutation.
Similar articles
-
Multigenerational Brazilian family with malignant hyperthermia and a novel mutation in the RYR1 gene.Braz J Med Biol Res. 2009 Dec;42(12):1218-24. Epub 2009 Nov 13. Braz J Med Biol Res. 2009. PMID: 19918671
-
North American malignant hyperthermia population: screening of the ryanodine receptor gene and identification of novel mutations.Anesthesiology. 2001 Sep;95(3):594-9. doi: 10.1097/00000542-200109000-00009. Anesthesiology. 2001. PMID: 11575529
-
RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.Hum Mutat. 2002 Aug;20(2):88-97. doi: 10.1002/humu.10098. Hum Mutat. 2002. PMID: 12124989
-
Malignant hyperthermia: a pharmacogenetic disease of Ca++ regulating proteins.Curr Mol Med. 2002 Jun;2(4):347-69. doi: 10.2174/1566524023362429. Curr Mol Med. 2002. PMID: 12108947 Review.
-
Ryanodine receptor mutations in malignant hyperthermia and central core disease.Hum Mutat. 2000;15(5):410-7. doi: 10.1002/(SICI)1098-1004(200005)15:5<410::AID-HUMU2>3.0.CO;2-D. Hum Mutat. 2000. PMID: 10790202 Review.
Cited by
-
RYR1 Sequence Variants in Myopathies: Expression and Functional Studies in Two Families.Biomed Res Int. 2019 Apr 21;2019:7638946. doi: 10.1155/2019/7638946. eCollection 2019. Biomed Res Int. 2019. PMID: 31165076 Free PMC article. Clinical Trial.
-
Next-generation sequencing approach to hyperCKemia: A 2-year cohort study.Neurol Genet. 2019 Aug 16;5(5):e352. doi: 10.1212/NXG.0000000000000352. eCollection 2019 Oct. Neurol Genet. 2019. PMID: 31517061 Free PMC article.
-
Single-amino-acid deletion in the RYR1 gene, associated with malignant hyperthermia susceptibility and unusual contraction phenotype.Am J Hum Genet. 2001 Jul;69(1):204-8. doi: 10.1086/321270. Epub 2001 May 29. Am J Hum Genet. 2001. PMID: 11389482 Free PMC article.
-
Exercise-induced rhabdomyolysis and stress-induced malignant hyperthermia events, association with malignant hyperthermia susceptibility, and RYR1 gene sequence variations.ScientificWorldJournal. 2013;2013:531465. doi: 10.1155/2013/531465. Epub 2013 Feb 10. ScientificWorldJournal. 2013. PMID: 23476141 Free PMC article. Review.
-
Screening for mutations in the RYR1 gene in families with malignant hyperthermia.J Mol Neurosci. 2003;21(1):35-42. doi: 10.1385/JMN:21:1:35. J Mol Neurosci. 2003. PMID: 14500992
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous
